Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Johnson

Showing results (171-180 of 221) with videos related to

Pageof 23
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 22, 2016
Long-term Follow-up of Patients Having False-Positive Multitarget Stool DNA Tests after Negative Screening Colonoscopy: The LONG-HAUL Cohort StudyThomas G Cotter, Kelli N Burger, Mary E Devens, et al.
Cancer Informatics|May 7, 2019
Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung CancerTao Wang, Rong Lu, Sunny Lai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancerVincent A Miller, David H Johnson, Lee M Krug, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 15, 2024
Effect of Patient Navigation on Completion of Lung Cancer Screening in Vulnerable PopulationsSheena Bhalla, Vijaya Natchimuthu, Jessica L Lee, et al.
Experimental Hematology & Oncology|November 22, 2014
Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trialTeresa Moran, Enriqueta Felip, Vicki Keedy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2023
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerDavid H Johnson, Louis Fehrenbacher, William F Novotny, et al.
JAMA Network Open|April 8, 2024
Trajectories of Health Care Contact Days for Patients With Stage IV Non-Small Cell Lung CancerArjun Gupta, Paul Nguyen, Danielle Kain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2005
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerRoy S Herbst, Diane Prager, Robert Hermann, et al.
Cancer Research|June 19, 2007
Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancerLi Yang, Joseph M Amann, Takefumi Kikuchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancerDavid H Johnson, Louis Fehrenbacher, William F Novotny, et al.
Pageof 23

Showing results (171-180 of 221) with videos related to

Sort By:
Pageof 23
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 22, 2016
Long-term Follow-up of Patients Having False-Positive Multitarget Stool DNA Tests after Negative Screening Colonoscopy: The LONG-HAUL Cohort StudyThomas G Cotter, Kelli N Burger, Mary E Devens, et al.
Cancer Informatics|May 7, 2019
Development and Validation of a Nomogram Prognostic Model for Patients With Advanced Non-Small-Cell Lung CancerTao Wang, Rong Lu, Sunny Lai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 31, 2003
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancerVincent A Miller, David H Johnson, Lee M Krug, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 15, 2024
Effect of Patient Navigation on Completion of Lung Cancer Screening in Vulnerable PopulationsSheena Bhalla, Vijaya Natchimuthu, Jessica L Lee, et al.
Experimental Hematology & Oncology|November 22, 2014
Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trialTeresa Moran, Enriqueta Felip, Vicki Keedy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2023
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung CancerDavid H Johnson, Louis Fehrenbacher, William F Novotny, et al.
JAMA Network Open|April 8, 2024
Trajectories of Health Care Contact Days for Patients With Stage IV Non-Small Cell Lung CancerArjun Gupta, Paul Nguyen, Danielle Kain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2005
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancerRoy S Herbst, Diane Prager, Robert Hermann, et al.
Cancer Research|June 19, 2007
Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancerLi Yang, Joseph M Amann, Takefumi Kikuchi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancerDavid H Johnson, Louis Fehrenbacher, William F Novotny, et al.
Pageof 23